Loading clinical trials...
Loading clinical trials...
A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD) Due to a Mutation in the RHO, PDE6A, or PDE6B Gene
Conditions
Interventions
SPVN06
Locations
6
United States
Bascom Palmer Eye Institute/University of Miami
Miami, Florida, United States
Mass Eye and Ear
Boston, Massachusetts, United States
Casey Eye Institute
Portland, Oregon, United States
UPMC Eye Center
Pittsburgh, Pennsylvania, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
CHNO XV-XX Paris - CIC 1423
Paris, France
Start Date
April 12, 2023
Primary Completion Date
September 1, 2025
Completion Date
September 1, 2030
Last Updated
September 16, 2025
NCT07548944
NCT05926583
NCT07174726
NCT07292987
NCT06789445
NCT04639635
Medical Director
CONTACT
Lead Sponsor
SparingVision
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions